Indian Pharmacopoeia Commission Issues Drug Safety Alert about Meftal Painkiller
Moneylife Digital Team 08 December 2023
Indian Pharmacopoeia Commission (IPC) has issued a drug safety alert about Meftal, a  painkiller, stating that its constituent, mefenamic acid, can cause adverse reactions. Meftal is a commonly used drug for menstrual cramps and rheumatoid arthritis. Meftal is manufactured and sold by Blue Cross Laboratories Ltd. 
 
In its alert, IPC says its preliminary analysis of adverse drug reactions (ADRs) from the pharmacovigilance programme of India (PvPI) database revealed that mefenamic acid could cause drug reactions with eosinophilia and systemic symptoms (DRESS) syndrome.
 
Doctors prescribe Meftal, the painkiller containing mefenamic acid for treating rheumatoid arthritis, osteoarthritis, dysmenorrhoea, mild to moderate pain, inflammation, fever and dental pain.
 
Mefenamic acid, also known as anthranilic acid, is a non-steroid anti-inflammatory drug (NSAID) used to relieve mild and moderate pains.
 
"Healthcare professionals, patients and consumers are advised to closely monitor the possibility of the ADR associated with the use of the suspected drug," the commission says in its alert.
Comments
Thariyan Tharayil
2 months ago
What about \'Meftal Spas\'
Thariyan Tharayil
Replied to Thariyan Tharayil comment 2 months ago
There is also one more called \'Big Spas\'. This ADR needs to be explained with list of identified reactions so that patients can identify and take remedial action. There is limited scope for ML to include every thing in this article but a link to some thing that patients can refer to would help.
Array
Free Helpline
Legal Credit
Feedback